Chimeric antigen receptor T-cell therapy (CAR-T) has came out as one of a potent and useful therapeutic intervention among the current initiatives of targeted anti-cancer therapies that will eradicate tumor cells, with lesser side effects. It will target tumor cells and strengthen the immune system of the patient against the tumor. CAR-T cell therapy is a type of treatment in which T-cells derived from patient’s blood are modified in the laboratory by adding the special protein receptor known as Chimeric Antigen Receptor (CAR) on the T-cells, which will bind to the infected tumor cells and kill them. It is based on the principle of using the instinctive potential of the immune system to target thereby destroying the cancer cells. The main characteristics that promote CAR-T cells suitable for use as effective therapeutic tools are target specificity, adaptability and the capability of retaining immunologic memory. This potential approach has been successfully used in the treatment of Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Leukemia, and others.
Most of the popular targets of CAR-T therapies have been developed against hematological cancers and solid tumors. The ongoing strategies have led to the discovery of several novel molecular targets. The area of investigation is very broad and shows the combining or sequencing of the immunotherapies that will target the immune pathways and sequencing an immunotherapeutic agent. It presents a robust clinical pipeline under development having more than 200 products in various stages of development. Still, 2018, only two products - Yescarta by Gilead Science and Kymriah by Novartis have made it into the market. Both the products have been approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL), a rare type of blood cancer. This is expected to add market growth over the forecast period. The success witnessed in early phase trials assessed the necessity of evaluating the treatment modality in multiple centers and in larger patients. Currently, 99 CAR T Cell-based therapies are found in the clinical pipeline, and most of them are found in Phase-I and Phase-I/II clinical trials. The KITE Pharma found to be in collaboration with the National Cancer Institute has developed anti-CD19 CAR T cell therapy of axicabtagene ciloleucel (KTE-C19) that is in the pre-registration phase. The first commercial application is anticipated to be available from 2020 of CAR T Cell therapy for the treatment of Mantle Non-Hodgkin's lymphoma.
The side effects of using CAR-T cell therapy can lead to cytokine release syndrome (CRS) and other neurological problems including seizures, coma, hallucinations, and delirium is anticipated to hinder the growth of the market. Increase in cancer incidences in adults and children, and the rise in the number of cancer patients with less response to alternative treatments is known to faster the growth of the market and expected to have a high demand for an effective and reliable therapeutic approach for improvement of the quality of patient lives. Further, increasing government initiatives for developing health care infrastructure and encouraging cell therapy research in cancer is going to fuel the market growth.
In future, the advancement in CAR T Cell therapy will be largely driven by academia and will need the support for the expensive early phase clinical trials, which will promisingly develop a new form of targeted, exportable immunotherapy for patients with cancer cells. CD-19 redirected chimeric antigen receptor is one of the immunotherapeutic modality, which has been recently demonstrated the efficiency in re-inducing the remission in patients with multiple relapses B-acute lymphoblastic leukemia.
This pipeline report segments the CAR T-cell therapy based on therapies employed that includes monotherapy and monotherapy +combination therapy, RoA (intravenous and undisclosed), therapeutic modalities (cell), targets for drugs under development (CD19, CD7, CD123, CD33, and undisclosed), drugs under development (phase I and phase I/II), and recruitment status (recruiting, not yet recruiting, and completed).
CAR builds of clinical stage therapies based on the generation of CAR-T product (first generation, second generation, third generation and fourth generation), type of vector (lentivirus, retrovirus, mRNA electroporation, sleeping beauty), type of binding domain (murine, humanized, fully human and rabbit-derived), and other vectors) and type of co-stimulatory domain used.
The major key players involved in developing the CAR T-cell therapy pipeline include Autolus, Bellicum, Bluebird, Celgene, Cellectis, Celyad, Eureka Therapeutics, and others.
Report Description: The report covers in-depth analysis on CAR T-Cell Therapy Pipeline Insights, 2019. The report assesses the CAR T-Cell Therapy pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application. In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in CAR T-Cell Therapy Pipeline. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.